No new catalysts or data points — the stock will continue to trade on ALTITUDE-AD expectations. Monitor for the EBD option exercise announcement in Q2 2026 as a potential near-term catalyst. The $128.4M cash runway into early 2027 removes near-term financing risk.
Price Chart
Executive Summary
Acumen Pharmaceuticals reported Q1 2026 results with a net loss of $20.7M ($0.33/share), narrower than the $28.8M loss ($0.48/share) in Q1 2025, driven by lower R&D spend post-ALTITUDE-AD enrollment completion. Cash increased to $128.4M following a $35.75M private placement, extending runway into early 2027. The filing is routine for a pre-revenue clinical-stage biotech — no new clinical data, no guidance changes, and the key catalyst (ALTITUDE-AD topline) remains on track for late 2026.
Key Financial Metrics
Key Facts
- Net loss of $20.7M for Q1 2026 vs $28.8M in Q1 2025
- EPS of -$0.33 vs -$0.48 year-over-year
- Cash, cash equivalents and marketable securities of $128.4M as of March 31, 2026
- Cash runway expected into early 2027
- ALTITUDE-AD Phase 2 topline results expected in late 2026 — no change in timeline
- EBD program IND filing targeted for mid-2027
- Company expects to exercise option to license two EBD candidates in Q2 2026
- R&D expenses decreased to $16.5M from $25.3M due to completion of ALTITUDE-AD enrollment
- Private placement in March 2026 raised $35.75M in gross proceeds
Financial Impact
No revenue; net loss improved by $8.1M YoY to $20.7M. Cash position strengthened by $11.5M sequentially to $128.4M due to private placement.
Risk Factors
- ALTITUDE-AD Phase 2 topline results in late 2026 are binary — failure would be devastating for a single-asset company
- Cash runway only into early 2027 — additional financing likely needed before commercialization
- No revenue and accumulating losses ($467.2M accumulated deficit)
- Dilution from 19.2% increase in shares outstanding (60.6M to 72.2M) due to private placement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033868 |
| Document: acumen_ncxcorporatexdeck.htm | 0001628280-26-033868 |
| Document: abos-20260512.htm | 0001628280-26-033868 |
| Document: 0001628280-26-033868-index-headers.html | 0001628280-26-033868 |
| Document: 0001628280-26-033868-index.html | 0001628280-26-033868 |
| Document: 0001628280-26-033868.txt | 0001628280-26-033868 |
| 8-K Data (Synthetic) | 0001628280-26-033868 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-3 | $2.27 | awaiting T+20 | — | $2.19 (+3.53%) |
Oct 26, 2026 1d ago | 8-K | $2.07 | awaiting T+20 | — | $2.19 (+5.85%) |
Oct 26, 2026 1d ago | Press Release | $2.05 | awaiting T+20 | — | $2.19 (+6.83%) |
Oct 22, 2026 5d ago | Press Release | $2.06 | awaiting T+20 | — | $2.19 (+6.31%) |
Oct 19, 2026 7d ago | Press Release | $2.02 | awaiting T+20 | — | $2.19 (+8.68%) |
Sep 16, 2026 5w ago | 8-K | $2.61 $1.82 | ▼ −30.46% | ▼ −33.64% | $2.19 (−16.09%) |
Aug 12, 2026 10w ago | Institutional Cluster | $2.51 $2.86 | ▲ +13.94% | ▲ +15.84% | $2.19 (−12.75%) |
Aug 12, 2026 10w ago | 8-K | $2.51 $2.86 | ▲ +13.94% | ▲ +15.84% | $2.19 (−12.75%) |
Aug 12, 2026 10w ago | Press Release | $2.51 $2.86 | ▼ −13.94% | ▼ −15.84% | $2.19 (+12.75%) |
Jun 17, 2026 18w ago | Insider Cluster | $2.26 $2.17 | ▼ −3.98% | ▼ −4.52% | $2.19 (−3.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers